Elicio Therapeutics Company
Elicio Therapeutics develops an immuno-tumor vaccine to treat cancer.
Investor Type:
Early Stage Venture
Investors Number:
5
Employee Number:
11-50
Last Funding Date:
2021
Headquarters:
Cambridge, Massachusetts, United States
Last Funding Type:
Series B
Total Funding:
148461801
Founded Date:
2011
Industry:
Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
Estimated Revenue:
Less than $1M